Navigation Links
MD Anderson Cancer Center joins Actinium Pharmaceuticals' (API) Multicenter Actimab-A Trial
Date:9/12/2012

NEW YORK, Sept. 12, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (API), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, announced that MD Anderson Cancer Center in Houston, Texas has joined the Company's ongoing Phase I/II trial in newly diagnosed patients with acute myeloid leukemia (AML).  The trial is designed to establish safety and efficacy of API's drug Actimab-A in AML patients over the age of 60.  Actimab-A treatment consists of the isotope Actinium 225 attached to the anti-CD33 monoclonal antibody lintuzumab (HuM195). 

"This is an important milestone in the development of our drug candidate," said Jack Talley, CEO of Actinium Pharmaceuticals.  "MD Anderson is a leading cancer treatment institution and treats more patients with acute myeloid leukemia than any other center in the world.  We view their joining our trial as a key vote of confidence for our innovative, world class technology."

MD Anderson is the third center to sign a clinical trial agreement with Actinium Pharmaceuticals, following Memorial Sloan Kettering Cancer Center (MSKCC) in New York, NY and Fred Hutchinson Cancer Research Center (FHCRC) in Seattle, Washington.

Phase I/II multi-center Actimab study will build on the previous phase I/II Bismab-A study with a less potent bismuth-213 (Bi-213) isotope and an earlier Actimab-A phase 1 study (where only a single dose of Actimab was administered).  The Phase II portion of the earlier Bismab-A study demonstrated the efficacy of API's alpha particle platform by producing a number of complete responses in difficult-to-treat relapsed, secondary and poor cytogenetics AML patients with no standard of care options available. The goal of the current study is to confirm efficacy and safety of Actimab-A using the same antibody targeting mechanism with the actinium isotope, produced by an improved method of manufacture, and to study the effect of mu
'/>"/>

SOURCE Actinium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Clinical Site Services Chris Trizna Contributing Author in Diana Anderson-Fosters Newest Release Global Issues in Patient Recruitment and Retention
2. MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020
3. Virobays Spectrum-Selective Cathepsin Inhibitor Shows Efficacy in Bone Cancer Model
4. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
5. NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer
6. Members of Congress, Cancer Experts Address Impact of Genetic Testing on Cancer
7. Masaryk Memorial Cancer Institute Reduces Losses and Administrative Overhead With Ekahau RTLS
8. BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelonas Vall dHebron Hospital in Biomarker Research for Personalized Cancer Therapies
9. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
10. New research points to benefits of innovative cobas® HPV test for primary screening as Englands cervical cancer screening programme includes the test in current HPV "triage" rollout
11. A New Type of Dendritic Cell-Based Cancer Vaccine has Received Approval for Clinical Tests and at the Same Time Secures Substantial Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Pennsylvanie, 18 septembre 2014 /PRNewswire/ ... en 1974, a été depuis ... compléter les évaluations cliniques traditionnelles par des ... Outcomes) et sur les impacts économiques des ... A cours d,une ...
(Date:9/18/2014)... September 18, 2014 OMICS Group ... globe to participate in the ‘Open Access Week’ ... to OMICS Group Pharma Journals from ... of the fastest emerging Sciences, accelerating with a ... services across the globe. The industry is gearing ...
(Date:9/18/2014)... dysplasia is a group of rare diseases that ... cartilage. Its onset hits at the fetal stage ... in the gene encoding fibroblast growth factor receptor ... of skeletal dysplasia, thanatophoric dysplasia (TD), a skeletal ... and is often lethal, and achondroplasia (ACH), which ...
(Date:9/18/2014)... weight loss and diabetes prevention, could actually hasten the ... do it in a surprising way: by changing the ... substantial population of bacteria residing in our intestines. These ... were published today in Nature . Among other ... Immunology Department, who led this research together with Prof. ...
Breaking Biology Technology:1974 - 2014 - Mapi fête ses 40 ans 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 3Researchers use iPS cells to show statin effects on diseased bone 2Researchers use iPS cells to show statin effects on diseased bone 3Gut bacteria, artificial sweeteners and glucose intolerance 2Gut bacteria, artificial sweeteners and glucose intolerance 3
... Elsevier announced today,that its flagship product Scopus, the world,s ... nearly doubling its Arts &,Humanities (A&H) titles. Access to ... April 2009. Currently the Scopus database contains 1,600,titles in ... Many countries will be better represented as ...
... Nov. 24 Imaging,Diagnostic Systems, Inc., (OTC Bulletin Board: ... pleased to announce the issuance of its,21st US Patent ... Digitization of the Temporal Point Spread,Function of the Detected ... (Logo: http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGO ) ...
... 24 Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ... an agreement with Baxter Oncology GmbH for the,commercial ... is developing picoplatin, its lead product candidate, as ... solid tumors. The Company is,evaluating picoplatin in ...
Cached Biology Technology:Scopus to Expand Arts & Humanities Coverage 2Scopus to Expand Arts & Humanities Coverage 3Imaging Diagnostic Systems is Recognized for Its Advanced Engineering in Time-Resolved Techniques by the US Patent Office 2Imaging Diagnostic Systems is Recognized for Its Advanced Engineering in Time-Resolved Techniques by the US Patent Office 3Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin 2Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin 3
(Date:9/18/2014)... form of camouflage: you don,t just blend in, the ... as uncommon as you might think. Kathryn Feller, from ... the larval life stages of many marine species are ... that most creatures cannot make transparent. Feller explains that ... individual eye unit with an opaque pigment to prevent ...
(Date:9/18/2014)... spend their entire lives nestling in the protective tentacles ... babies they sometimes travel hundreds of kilometres across the ... reef fish has been predicted, this is the first ... distant populations has been observed. , Dr Steve Simpson, ... the University of Exeter, and colleagues from the Australian ...
(Date:9/17/2014)... instrumental in the creation of the Santa Ana Wildfire ... fire threat potential of the powerful, hot, dry Santa ... inferno. The index was introduced Sept. 17 by the ... Diego Gas and Electric. , The index includes four ... be used to help fire agencies and other emergency ...
Breaking Biology News(10 mins):Transparent larvae hide opaque eyes behind reflections 2Expedition finds Nemo can travel great distances to connect populations 2Expedition finds Nemo can travel great distances to connect populations 3UCLA scientists play key role in developing new Santa Ana Wildfire Threat Index 2
... Science of Food and Agriculture shows that konjac gum ... of E. coli and Salmonella bacteria. The study by ... Centre, the Netherlands, shows that these foodstuffs act as binders ... to the fibrous foods instead of the gut cells of ...
... published online today in the International Journal of Obesity ... of a reduced-calorie diet, helps overweight adults lose more weight ... breakfast of equal calories. [1] This study supports previous ... of Nutrition , which showed that people who ate eggs ...
... Dalton, professor and Georgia Research Alliance Eminent Scholar of ... awarded $9.2 million as part of a major new ... Sciences, part of the National Institutes of Health. ... molecular biology, will address the molecular underpinnings of the ...
Cached Biology News:Adults who eat eggs for breakfast lose 65 percent more weight 2Adults who eat eggs for breakfast lose 65 percent more weight 3UGA researchers win $9.2 million stem cell grant from NIH 2
... were designed for full-length gene cloning and ... identify the desired cDNA clone. The first ... "Master Plate," where each well contains plasmid ... positive well(s) by gel electrophoresis of the ...
... The Rapid-Screen cDNA Library Panels were ... just three sets of PCRs to identify ... analysis is performed in a 96-well "Master ... from 5,000 clones. Having identified the positive ...
... The DSQ II (Dual-Stage Quadrupole) ... the world leader in analytical instrumentation, introduces ... the DSQ II. Based on the ... DSQ and PolarisQ GC/MS systems, the DSQ ...
... Panels were designed for full-length gene cloning ... to identify the desired cDNA clone. The ... 96-well "Master Plate," where each well contains ... the positive well(s) by gel electrophoresis of ...
Biology Products: